Cargando…

Updated Australian guidelines for mild asthma: what’s changed and why?

The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta(2) ago...

Descripción completa

Detalles Bibliográficos
Autor principal: Reddel, Helen K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738702/
https://www.ncbi.nlm.nih.gov/pubmed/33363311
http://dx.doi.org/10.18773/austprescr.2020.076
_version_ 1783623176339587072
author Reddel, Helen K
author_facet Reddel, Helen K
author_sort Reddel, Helen K
collection PubMed
description The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta(2) agonists such as a salbutamol inhaler For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta(2) agonist The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations
format Online
Article
Text
id pubmed-7738702
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-77387022020-12-23 Updated Australian guidelines for mild asthma: what’s changed and why? Reddel, Helen K Aust Prescr Article The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta(2) agonists such as a salbutamol inhaler For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta(2) agonist The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations NPS MedicineWise 2020-12-01 2020-12 /pmc/articles/PMC7738702/ /pubmed/33363311 http://dx.doi.org/10.18773/austprescr.2020.076 Text en (c) NPS MedicineWise http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Article
Reddel, Helen K
Updated Australian guidelines for mild asthma: what’s changed and why?
title Updated Australian guidelines for mild asthma: what’s changed and why?
title_full Updated Australian guidelines for mild asthma: what’s changed and why?
title_fullStr Updated Australian guidelines for mild asthma: what’s changed and why?
title_full_unstemmed Updated Australian guidelines for mild asthma: what’s changed and why?
title_short Updated Australian guidelines for mild asthma: what’s changed and why?
title_sort updated australian guidelines for mild asthma: what’s changed and why?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738702/
https://www.ncbi.nlm.nih.gov/pubmed/33363311
http://dx.doi.org/10.18773/austprescr.2020.076
work_keys_str_mv AT reddelhelenk updatedaustralianguidelinesformildasthmawhatschangedandwhy